Corbus Pharmaceuticals Holdings Inc Stock
Corbus Pharmaceuticals Holdings Inc Stock price
Key metrics
| Market capitalization | $117.53m |
| Enterprise Value | $-38.51m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 1.04 |
| P/B ratio (TTM) P/B ratio | 0.78 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-46.22m |
| Free Cash Flow (TTM) Free Cash Flow | $-36.86m |
| Cash position | $159.65m |
Is Corbus Pharmaceuticals Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.
Corbus Pharmaceuticals Holdings Inc Stock Analysis
Analyst Opinions
9 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:
Analyst Opinions
9 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:
Financial data from Corbus Pharmaceuticals Holdings Inc
| Sep '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.70 -0.70 |
33%
33%
|
|
| EBITDA | -46 -46 |
2%
2%
|
EBIT (Operating Income) EBIT | -46 -46 |
1%
1%
|
| Net Profit | -39 -39 |
18%
18%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Corbus Pharmaceuticals Holdings Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Corbus Pharmaceuticals Holdings Inc Stock News
Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
| Head office | United States |
| CEO | Yuval Cohen |
| Employees | 19 |
| Founded | 2009 |
| Website | www.corbuspharma.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
